By clicking “Subscribe” you agree to our Terms and Conditions and Privacy Policy.
Estradiol is the gold standard for hormone replacement — but how it’s delivered to your body is just as important as the hormone itself. Different delivery methods produce different blood-level patterns, carry different risk profiles, target different tissues, and fit different lifestyles.
Luvo’s hormone replacement program offers five distinct estradiol formulations — more than most competitors provide. This comprehensive comparison helps you understand how each works, what it’s best for, and how they can be combined for complete symptom management.
Three of Luvo’s estradiol options provide systemic delivery — meaning the estradiol enters your bloodstream and circulates throughout your body, reaching estrogen receptors in the brain, bones, cardiovascular system, and other tissues.
Estradiol tablets are taken orally once daily. The hormone is absorbed through the GI tract and undergoes first-pass liver metabolism. This hepatic processing increases the production of certain liver proteins, including clotting factors and SHBG. The advantages are simplicity and familiarity. The clinical consideration is a modestly increased risk of venous thromboembolism compared to transdermal delivery.
Estradiol cream is applied to the skin daily. It absorbs through the dermis directly into the bloodstream, bypassing the liver. This avoids the clotting factor increase associated with oral delivery. The cream offers flexible dosing and a safe thrombotic profile. The practical trade-off is a brief daily application routine.
Estradiol patches are applied to the skin and replaced once or twice weekly. Like cream, they deliver estradiol transdermally. The unique advantage of patches is exceptionally steady hormone levels — no daily peaks and troughs. They offer the most consistent delivery, the best thrombotic safety, and the lowest maintenance routine of any systemic option.
Two of Luvo’s estradiol options deliver the hormone directly to the vaginal and urogenital tissues, with minimal absorption into the systemic circulation.
Estradiol vaginal gel is applied intravaginally using a measured applicator. It distributes across the vaginal walls and provides concentrated estrogen to the tissue that needs it most. Vaginal gel is effective for treating vaginal dryness, painful intercourse, vaginal atrophy, and urinary symptoms.
Estradiol vaginal tablets are small tablets inserted vaginally. They dissolve in place and release estradiol locally. The tablet format is clean, precise, and mess-free. Like the gel, it effectively treats GSM symptoms.
Both vaginal formulations produce very low systemic estradiol levels — typically remaining within the normal postmenopausal range. This makes them appropriate for women who need localized therapy but want to avoid or minimize systemic estrogen exposure.
Many women benefit from using more than one estradiol formulation simultaneously. This isn’t over-treatment — it’s targeted treatment.
The most common combination is a systemic formulation (tablets, cream, or patches) for hot flashes, mood, sleep, and bone protection, plus a vaginal formulation (gel or tablets) for concentrated urogenital symptom relief. Systemic estradiol provides some benefit to vaginal tissues, but many women find it insufficient for significant GSM symptoms. Adding vaginal estradiol provides the concentrated local effect these tissues need.
Your Luvo provider designs the combination based on your specific symptom profile. A woman whose primary complaints are hot flashes and insomnia might start with patches alone. If vaginal dryness develops later, vaginal gel or tablets can be added without changing the systemic component.
This modular approach — building and adjusting a multi-formulation protocol over time — is one of the key advantages of Luvo’s 10-medication program.
Here’s a practical summary to aid your decision.
Estradiol tablets are best for women who want simple daily dosing and have no elevated clotting risk. Application is a daily pill with no skin considerations. They offer the most straightforward routine but do carry modestly elevated thrombotic risk.
Estradiol cream is best for women wanting transdermal safety with flexible dosing. Application is daily to the skin with a brief drying period. It offers good safety and dose adjustability.
Estradiol patches are best for women wanting the steadiest levels and lowest maintenance. Application is once or twice weekly to the skin. They offer the most consistent delivery and best thrombotic safety.
Estradiol vaginal gel is best for vaginal dryness and urogenital symptoms. Application is intravaginal with an applicator. It provides excellent localized therapy with minimal systemic absorption.
Estradiol vaginal tablets are best for the same symptoms as gel with a cleaner, more precise format. Application is a small tablet inserted vaginally. It provides the same targeted relief with less mess.
Explore each option in detail: estradiol tablets, estradiol cream, estradiol patches, estradiol vaginal gel, and estradiol vaginal tablets. Or visit Luvo’s hormone replacement program for a comprehensive evaluation.
“Should I take HRT?” is one of the most common questions in women’s health — and one of the hardest to answer with a simple yes or no. The right answer depends on your age, how long ago you reached menopause, your symptom severity, your health history, your family history, and your personal values and risk tolerance.
Luvo’s hormone replacement program begins with a thorough clinical evaluation precisely because this question deserves a thoughtful, individualized answer — not a one-minute online quiz.
One of the most important concepts in modern HRT prescribing is the “window of opportunity” — the period during which HRT initiation provides the greatest benefits with the lowest risks.
This window is generally defined as within 10 years of menopause onset or before age 60. Within this window, the evidence shows that HRT provides significant symptom relief for vasomotor symptoms, sleep disruption, and mood changes, protects bone density and reduces fracture risk, may provide cardiovascular benefit (or at minimum does not increase cardiovascular risk), and has a favorable overall benefit-to-risk ratio.
Outside this window — in women who are more than 10 years past menopause or over 60 — the benefit-risk calculation changes. Starting systemic HRT later may carry more cardiovascular risk, particularly with oral formulations. However, vaginal estradiol for urogenital symptoms remains safe and appropriate at any age, and non-hormonal options for vasomotor symptoms are available regardless of timing.
This is why early evaluation matters. If you’re in your late 40s or early 50s and experiencing menopause symptoms, the window is open now — and Luvo’s program can help you take advantage of it.
Several groups of women have especially strong indications for HRT.
Women with moderate to severe hot flashes and night sweats that significantly affect quality of life, sleep, or daily functioning have the most clear-cut indication for systemic estradiol therapy.
Women with premature menopause (before age 40) or early menopause (before age 45) are strongly recommended to use HRT at least until the average age of natural menopause (51) to protect bone, cardiovascular, and cognitive health. Without HRT, these women face accelerated aging of multiple organ systems.
Women with significant GSM symptoms including vaginal dryness, painful intercourse, and recurrent UTIs benefit from vaginal estradiol even if they don’t need systemic therapy.
Women at elevated risk for osteoporosis, particularly those with low bone density, family history of fractures, or other risk factors, may benefit from the bone-protective effects of estradiol.
Women experiencing significant menopausal mood symptoms, particularly those that coincide with the onset of perimenopause and don’t respond adequately to other interventions.
Certain conditions require careful consideration or may preclude some forms of HRT.
Absolute contraindications to systemic estrogen include known or suspected estrogen-dependent cancer (certain breast cancers), active or recent venous thromboembolism (blood clots), active stroke or heart attack, undiagnosed abnormal vaginal bleeding, and active liver disease or dysfunction.
Conditions requiring careful evaluation include a family history of breast cancer (which increases baseline risk but is not an absolute contraindication), a history of blood clots (transdermal estradiol may be an option since it doesn’t increase clotting risk), migraine with aura (transdermal estrogen is generally safer than oral), gallbladder disease (transdermal delivery avoids hepatic effects that exacerbate this), and endometriosis history.
For women with contraindications to estrogen, Luvo’s program offers non-hormonal options (Paroxetine and Desvenlafaxine) that provide meaningful symptom relief without estrogen exposure. Vaginal estradiol, with its minimal systemic absorption, may also be appropriate for some women with relative estrogen contraindications — your Luvo provider will evaluate this based on your specific situation.
Whether HRT is right for you is a clinical decision that deserves expert evaluation — not a decision based on fear, a friend’s experience, or a 20-year-old news story.
Luvo’s hormone replacement program starts with a comprehensive health assessment and clinical consultation. Your provider will review your symptom severity, menopause stage, health history, risk factors, and personal preferences to determine whether HRT is appropriate and which specific approach is optimal.
With 10 medications available, there’s almost always a safe and effective option — even for women with complex health histories. Systemic estradiol for eligible candidates, vaginal estradiol for localized symptoms, testosterone for libido and vitality, and non-hormonal options for women who need an alternative.
The worst option is no treatment when treatment would help. If menopause symptoms are affecting your quality of life, start the conversation. Visit Luvo’s hormone replacement program to begin your assessment.
No two women experience menopause the same way. Some are primarily bothered by hot flashes. Others struggle most with vaginal dryness or painful sex. Some are blindsided by mood changes and cognitive fog. And many deal with multiple symptoms simultaneously, each requiring its own treatment consideration.
The problem with one-size-fits-all HRT programs is that they treat menopause as a single condition with a single solution. Luvo’s program takes a symptom-specific approach, matching treatments to what you’re actually experiencing. This guide maps common menopause symptoms to the Luvo medications most effective for each.
Vasomotor symptoms are the hallmark of menopause, affecting up to 80% of women. They’re caused by estrogen-withdrawal-driven instability in the hypothalamic thermoregulatory center.
First-line treatments from Luvo include systemic estradiol, which directly addresses the underlying estrogen deficit. Estradiol tablets, cream, or patches all effectively reduce hot flash frequency and severity, typically by 75–95%. Transdermal options (cream and patches) are preferred for women with clotting risk factors.
For women who cannot take estrogen, Paroxetine is the FDA-approved non-hormonal option, reducing hot flash frequency by 33–65%. Desvenlafaxine offers potentially greater reduction at 55–70% and the added benefit of norepinephrine activity for energy and mood.
Night sweats are essentially nocturnal hot flashes and respond to the same treatments. Because they disrupt sleep, addressing them often produces cascading improvements in daytime energy, mood, and cognitive function.
Genitourinary syndrome of menopause (GSM) is progressive and affects the majority of postmenopausal women.
Localized vaginal estradiol is the most direct and effective treatment. Luvo’s estradiol vaginal gel and vaginal tablets deliver estrogen directly to the affected tissues with minimal systemic absorption. Most women experience significant improvement within 2–4 weeks, with continued improvement over 3 months.
Systemic estradiol (tablets, cream, or patches) provides some vaginal benefit as well, but many women with GSM need the additional concentrated local therapy that vaginal formulations provide.
For women who cannot use any form of estrogen, regular use of vaginal moisturizers and lubricants combined with Paroxetine or Desvenlafaxine for any accompanying vasomotor symptoms is the recommended alternative approach.
Declining sexual desire is one of the most distressing menopause symptoms and one of the most undertreated. It has both estrogen and testosterone components.
Testosterone therapy is the most evidence-based treatment for hypoactive sexual desire in postmenopausal women. Luvo’s testosterone injection, tablets, or gel can be added to an estradiol regimen (or used alone) to address libido directly. The 2019 Lancet meta-analysis confirmed that testosterone significantly improves desire, arousal, orgasm, and satisfaction in postmenopausal women.
Estradiol addresses the physical component by improving vaginal health, lubrication, and comfort during intercourse. When sex is no longer painful (thanks to vaginal estradiol), desire often improves as well.
The combination of systemic estradiol plus vaginal estradiol plus testosterone addresses sexual dysfunction from every angle — hormonal drive, physical comfort, and tissue health. This comprehensive approach is one of Luvo’s key differentiators.
Mood symptoms during menopause are driven by multiple factors: estrogen’s effects on serotonin and other neurotransmitters, sleep disruption from night sweats, and the psychological impact of the transition itself.
Estradiol therapy often produces significant mood improvement, particularly when mood symptoms are clearly linked to the menopausal transition. Stabilizing estrogen levels helps stabilize the neurochemical environment.
Paroxetine and Desvenlafaxine address mood symptoms through direct serotonergic and noradrenergic mechanisms. For women whose mood symptoms are severe, these medications may be used alongside or instead of estradiol. Desvenlafaxine’s SNRI mechanism may be particularly effective for the combination of depression, fatigue, and hot flashes.
Testosterone can contribute to improved mood, confidence, and overall sense of well-being. It’s rarely used as a primary mood treatment but can provide meaningful benefit as part of a comprehensive protocol.
Cognitive changes, persistent fatigue, and loss of lean mass are increasingly recognized as significant menopause symptoms driven by both estrogen and testosterone decline.
Estradiol supports cognitive function through its effects on cerebral blood flow, synaptic plasticity, and neurotransmitter function. Many women report improved mental clarity within weeks of starting estradiol therapy.
Testosterone’s role in energy, cognitive sharpness, and muscle maintenance makes it a valuable addition for women experiencing these symptoms. The anabolic effects of testosterone help maintain the lean mass and metabolic rate that decline during menopause.
Desvenlafaxine’s norepinephrine activity can address fatigue and cognitive fog independently of hormonal mechanisms, making it useful either as a complement to HRT or as a standalone option.
Luvo’s program recognizes that these symptoms often require a multi-medication strategy. Your provider will build a protocol that addresses your complete symptom picture. Visit the hormone replacement program to get started.
One of the biggest mistakes in women’s healthcare is treating menopause as a single event rather than a multi-year transition with distinct phases. A 44-year-old woman experiencing her first irregular periods and occasional hot flashes has very different needs than a 55-year-old woman who has been postmenopausal for four years and is dealing with vaginal atrophy and bone loss.
Yet many HRT programs — and many providers — apply the same approach regardless of stage. Luvo’s hormone replacement program is designed around the reality that different phases require different treatment strategies, and our 10-medication toolkit gives providers the flexibility to match treatment to phase.
Perimenopause typically begins in the mid-40s (though it can start in the late 30s) and lasts an average of 4–8 years. It’s defined by fluctuating and declining ovarian function, with estrogen levels that can swing wildly — sometimes higher than normal, sometimes crashing to postmenopausal levels, sometimes changing dramatically within a single cycle.
This hormonal chaos produces symptoms that can be confusing and unpredictable. Irregular periods are the hallmark — cycles may become shorter, longer, heavier, lighter, or skip entirely. Hot flashes may come and go. Sleep disruption often begins in earnest. Mood symptoms including anxiety, irritability, and depression are frequently reported — and are often the first symptoms women seek help for, sometimes without realizing the hormonal connection.
Brain fog and difficulty concentrating catch many perimenopausal women off guard. The cognitive changes can be alarming, particularly for women in demanding careers who rely on mental sharpness.
Because hormone levels during perimenopause are unpredictable rather than consistently low, treatment approaches need to be flexible and responsive.
Managing perimenopause requires accommodating hormonal variability rather than simply replacing a consistent deficit.
Low-dose estradiol in tablet, cream, or patch form can stabilize the hormonal fluctuations that drive symptoms. The goal isn’t to replace estrogen (the ovaries are still producing it, albeit irregularly) but to smooth out the peaks and valleys. Transdermal formulations may be particularly useful because they provide steady delivery that counterbalances the ovarian instability.
Non-hormonal options are sometimes the right starting point for perimenopausal women. Paroxetine or Desvenlafaxine can address the mood symptoms and hot flashes that are often the primary complaints during this phase, without introducing additional hormones into an already fluctuating system.
Testosterone may be relevant for perimenopausal women already experiencing libido decline and fatigue, though it’s more commonly introduced later. Luvo’s availability of testosterone in injection, tablet, and gel form means it can be added when the clinical picture warrants.
The key during perimenopause is regular reassessment. Symptoms and hormonal status evolve continuously, and treatment should evolve with them. Luvo’s ongoing provider relationship supports this adaptive approach.
After 12 months without a period, you’ve reached menopause. From this point forward, estrogen levels are consistently low and continue to decline gradually. The treatment approach shifts from managing fluctuations to addressing a stable, ongoing hormone deficit.
Systemic estradiol becomes more clearly indicated if you’re experiencing hot flashes, night sweats, sleep disruption, mood changes, or want the bone and cardiovascular protection that estrogen provides within the window of opportunity. Your Luvo provider will recommend tablets, cream, or patches based on your risk profile and preferences.
Vaginal estradiol often becomes increasingly important as GSM symptoms develop or worsen in postmenopause. Many women need both systemic and localized therapy to address the full spectrum of symptoms. Luvo’s vaginal gel and vaginal tablets provide targeted relief for urogenital concerns.
Testosterone therapy becomes more relevant as the combined effect of ovarian and adrenal testosterone decline becomes clinically significant. Many postmenopausal women who’ve been on estradiol-only HRT experience a dramatic quality-of-life improvement when testosterone is added.
Non-hormonal options remain available for women entering postmenopause who have contraindications to estrogen or who have found Paroxetine or Desvenlafaxine effective during perimenopause and wish to continue.
The transition from perimenopause through menopause and into postmenopause is a years-long journey, and your treatment needs will change along the way. A protocol that works at 46 may need significant revision by 52.
Luvo’s program is designed for this reality. Our providers don’t just prescribe a treatment and move on — they partner with you through the entire transition, adjusting medications, doses, and delivery methods as your body and symptoms evolve.
With 10 medications available, there’s always room to optimize. Starting with a non-hormonal approach and adding estradiol when appropriate. Switching from oral to transdermal if risk factors emerge. Adding vaginal estradiol as GSM develops. Incorporating testosterone when libido and energy become priorities. The flexibility is the point.
Visit Luvo’s hormone replacement program to begin your evaluation, or explore our options: estradiol tablets, cream, patches, vaginal gel, vaginal tablets, testosterone injection, tablets, gel, Paroxetine, and Desvenlafaxine.
The Women’s Health Initiative (WHI) study, published in 2002, is the most influential — and most misunderstood — study in the history of hormone replacement therapy. Its initial results, which were widely reported as showing that HRT causes breast cancer and heart disease, led to millions of women abruptly stopping treatment and a generation of providers becoming afraid to prescribe it.
The human cost of this overreaction has been enormous. Women suffered through severe menopause symptoms unnecessarily. Rates of osteoporotic fractures increased. The gap between what the evidence actually shows and what many women (and some providers) believe about HRT remains one of the biggest failures of medical communication in modern history.
This article provides a clear, evidence-based assessment of what we actually know about HRT safety in 2026.
The WHI studied two specific regimens: oral conjugated equine estrogens (Premarin) plus medroxyprogesterone acetate (Provera) in women with a uterus, and Premarin alone in women who’d had a hysterectomy.
The estrogen-only arm actually showed a decreased risk of breast cancer and no increased cardiovascular risk. It was stopped early simply because it was part of the same administrative trial as the combination arm.
The combination arm showed a small increased risk of breast cancer (8 additional cases per 10,000 women per year) and a small increased risk of cardiovascular events. However, these risks were concentrated in women who started HRT more than 10 years after menopause and were over age 60 — a population very different from the typical woman who begins HRT in her early 50s.
Critically, the WHI used oral conjugated equine estrogens (derived from horse urine, containing multiple estrogen compounds) and a synthetic progestin (medroxyprogesterone acetate) — not the bioidentical estradiol and micronized progesterone that modern HRT typically uses. Subsequent research has shown that bioidentical formulations and transdermal delivery have substantially different risk profiles.
Breast cancer risk with modern HRT is more nuanced than headlines suggest. Estrogen-only therapy does not increase breast cancer risk and may reduce it. The combination of estrogen plus micronized progesterone (the bioidentical progestogen) appears to carry less breast cancer risk than the synthetic progestins used in the WHI. When risk does exist, it’s small in absolute terms and similar to risks associated with common lifestyle factors like alcohol consumption, obesity, and sedentary behavior.
Cardiovascular risk depends heavily on timing. The “timing hypothesis” is now well-established: women who start HRT within 10 years of menopause or before age 60 show neutral or even beneficial cardiovascular effects. Women who start HRT later may face increased risk. This window of opportunity is a key consideration in Luvo’s prescribing approach.
Venous thromboembolism (blood clot) risk is increased with oral estrogen but not with transdermal estrogen. This is one of the most clinically actionable findings in modern HRT research — and it’s why Luvo offers transdermal options (cream and patches) alongside tablets.
Stroke risk shows a similar pattern to clotting risk: modestly increased with oral estrogen, not increased with transdermal delivery, and dose-dependent. Using the lowest effective dose and transdermal delivery minimizes this concern.
Luvo’s hormone replacement program is designed with risk minimization built into every level.
Formulation selection matters. Luvo uses bioidentical estradiol, not conjugated equine estrogens. The availability of transdermal options (cream and patches) allows women with clotting risk factors to avoid oral estrogen entirely.
Route-of-delivery matching means your provider recommends the delivery method based on your risk profile, not just convenience. Women with elevated thrombotic risk are guided toward transdermal options. Women with predominantly vaginal symptoms may use localized therapy with minimal systemic exposure.
Non-hormonal alternatives ensure that women who cannot safely use estrogen still have effective treatment options. Paroxetine and Desvenlafaxine provide meaningful relief without any hormonal exposure.
Timing considerations are respected. Luvo’s providers follow the evidence-based window of opportunity, recommending HRT initiation for appropriate candidates within 10 years of menopause onset.
Ongoing monitoring through regular follow-ups ensures that treatment remains appropriate and effective over time, with dose adjustments as needed.
This comprehensive, evidence-informed approach to risk management is what distinguishes Luvo from competitors that offer a limited menu of options with minimal clinical nuance. Explore the full hormone replacement program.
Hormone replacement therapy is the most effective treatment for menopause symptoms, but it’s not right for everyone. Women with hormone-receptor-positive breast cancer, a history of blood clots or stroke, active liver disease, or certain other conditions may be advised against estrogen therapy. Others may simply prefer a non-hormonal approach.
These women haven’t been well-served by the healthcare system. For too long, the message has been: if you can’t take hormones, just tough it out. That’s not acceptable when effective non-hormonal options exist.
Luvo’s hormone replacement program includes two evidence-based non-hormonal medications: Paroxetine and Desvenlafaxine. Both have strong clinical evidence for reducing the frequency and severity of hot flashes and night sweats, and both offer additional benefits for the mood and sleep disruption that often accompany menopause.
Paroxetine (marketed as Brisdelle at the specific low dose approved for vasomotor symptoms) holds a unique distinction: it’s the only non-hormonal medication with FDA approval specifically for the treatment of moderate to severe hot flashes associated with menopause.
Paroxetine is a selective serotonin reuptake inhibitor (SSRI). At the doses used for menopause, it modulates serotonin activity in the thermoregulatory center of the hypothalamus — the brain region that controls body temperature. In menopause, declining estrogen destabilizes this thermoregulatory center, narrowing the body’s “thermoneutral zone” and triggering hot flashes and night sweats in response to minor temperature fluctuations. By stabilizing serotonergic signaling in this area, Paroxetine widens the thermoneutral zone and reduces the frequency and intensity of vasomotor episodes.
Clinical trials showed that Paroxetine reduced the frequency of moderate to severe hot flashes by approximately 33–65% compared to placebo, with significant improvements in hot flash severity as well. Most women notice improvement within 1–2 weeks of starting treatment.
Beyond vasomotor symptoms, Paroxetine can provide additional benefits for the anxiety, irritability, and mood instability that commonly accompany menopause. This dual action makes it particularly valuable for women dealing with both physical and emotional symptoms.
Desvenlafaxine is a serotonin-norepinephrine reuptake inhibitor (SNRI) that affects both serotonin and norepinephrine — two neurotransmitters involved in thermoregulation, mood, and pain processing. While not FDA-approved specifically for vasomotor symptoms (it’s approved for depression), it has robust clinical evidence for hot flash reduction and is widely used off-label for this purpose.
Studies have demonstrated that Desvenlafaxine reduces hot flash frequency by 55–70% compared to placebo, with reductions in hot flash severity as well. Some comparative data suggests it may be slightly more effective than SSRIs for vasomotor symptoms, possibly due to its additional norepinephrine activity.
The dual serotonin-norepinephrine mechanism provides several potential advantages. It addresses the mood, anxiety, and depressive symptoms that frequently coexist with menopause. Norepinephrine activity may contribute to improved energy and reduced fatigue. And its effects on pain pathways may benefit women experiencing the musculoskeletal pain that is increasingly recognized as a menopause symptom.
Desvenlafaxine is taken once daily, has a relatively straightforward side-effect profile, and doesn’t require the gradual titration that some other medications in this class need.
Both medications effectively reduce hot flashes, but they have different profiles that may make one more suitable than the other for individual patients.
Paroxetine may be preferred if FDA-approved status for vasomotor symptoms is important to you or your provider, if anxiety is a predominant accompanying symptom (SSRIs are first-line for anxiety disorders), or if you’re taking tamoxifen — though it’s important to note that Paroxetine can interact with tamoxifen by inhibiting CYP2D6, the enzyme that converts tamoxifen to its active form. This interaction is clinically significant and should be discussed with your oncologist. In this case, Desvenlafaxine is often the better choice.
Desvenlafaxine may be preferred if you want maximum hot flash reduction (some evidence suggests slightly greater efficacy), if depression or significant mood symptoms are present alongside vasomotor symptoms, if fatigue and low energy are prominent complaints (norepinephrine activity may help), if you’re on tamoxifen (Desvenlafaxine has less CYP2D6 interaction), or if musculoskeletal pain is a significant symptom.
It’s important to reframe how we think about non-hormonal menopause treatment. These aren’t consolation prizes for women who can’t take estrogen. They’re legitimate, effective treatments that address real pathophysiology — and for some women, they may be the optimal choice even if hormonal therapy is available.
Women whose primary symptoms are vasomotor (hot flashes and night sweats) without significant vaginal or bone concerns may find that Paroxetine or Desvenlafaxine provides sufficient relief without the complexity of hormonal management. Women dealing with both menopause symptoms and depression or anxiety may benefit from the dual therapeutic action of these medications.
Luvo’s program is designed to provide the right treatment, not just the most common one. Whether your optimal protocol involves estradiol, testosterone, non-hormonal medications, or a combination, your Luvo provider has the toolkit to make it happen.
When women think about hormone replacement therapy, estrogen dominates the conversation. And while estrogen is critically important, focusing on it exclusively leaves out a hormone that’s equally vital for women’s health and quality of life: testosterone.
Yes, testosterone. It’s not just a male hormone. Women produce testosterone in the ovaries and adrenal glands, and it plays essential roles in female physiology — roles that become painfully apparent when levels decline.
By menopause, a woman’s testosterone level is approximately 50% of what it was in her 20s. This decline contributes to symptoms that estrogen replacement alone doesn’t fully address: low libido, fatigue, loss of muscle mass, brain fog, and diminished sense of well-being. Yet most HRT programs focus almost exclusively on estrogen.
Luvo’s hormone replacement program recognizes testosterone as a critical component of comprehensive HRT, offering it in three formulations: injection, tablets, and gel.
Testosterone’s effects in women are wide-ranging and clinically significant.
Sexual desire and arousal are directly influenced by testosterone. It’s the primary hormone driving libido in women, acting on androgen receptors in the brain that regulate sexual motivation and pleasure. The decline in sexual desire that many women experience during and after menopause correlates closely with falling testosterone levels — and often doesn’t respond to estrogen therapy alone.
Energy and vitality are supported by testosterone’s effects on mitochondrial function, red blood cell production, and overall metabolic rate. Women with low testosterone frequently report a pervasive lack of energy that goes beyond what sleep and lifestyle adjustments can fix.
Muscle mass and bone density are maintained partly through testosterone’s anabolic effects. While estrogen gets most of the attention for bone health, testosterone contributes significantly to both bone mineralization and muscle protein synthesis. The loss of lean mass and increasing frailty in postmenopausal women is driven by declines in both hormones.
Cognitive function benefits from testosterone’s effects on brain health. Androgen receptors are distributed throughout the brain, and testosterone influences mood, mental clarity, memory, and cognitive processing speed.
Mood and well-being are affected in ways that overlap with but are distinct from estrogen’s effects. Many women describe testosterone’s impact as a restored sense of confidence, assertiveness, and general vitality that estrogen alone doesn’t provide.
Testosterone dosing for women is fundamentally different from men — women need approximately one-tenth the dose. Luvo’s formulations are specifically designed for female physiology.
Testosterone injection offers precise dosing and consistent absorption. Injections are administered on a regular schedule (often weekly or biweekly) and provide reliable blood levels. This option suits women who want the most controlled delivery and are comfortable with injection.
Testosterone tablets provide an oral option for women who prefer not to use topicals or injections. Oral testosterone for women is dosed carefully to achieve physiological female levels without exceeding the appropriate range.
Testosterone gel is applied topically in small amounts, typically to the inner arm or thigh. The gel absorbs through the skin and provides a steady testosterone delivery. Many women find this the most convenient and easiest option to incorporate into their daily routine.
Your Luvo provider will recommend the formulation and dose that best suits your hormonal profile, symptoms, and preferences. Explore each option: testosterone injection, testosterone tablets, and testosterone gel.
The use of testosterone in women is supported by a growing body of clinical evidence.
A landmark systematic review and meta-analysis published in The Lancet Diabetes and Endocrinology in 2019, analyzing 46 randomized controlled trials, found that testosterone therapy in women significantly improved sexual function, including desire, arousal, orgasm, and satisfaction. The benefits were consistent across postmenopausal women whether or not they were also taking estrogen.
The Global Consensus Position Statement on the Use of Testosterone Therapy for Women, published in 2019 and endorsed by multiple international medical societies, concluded that testosterone therapy at physiological female doses is effective for hypoactive sexual desire disorder in postmenopausal women and is associated with a favorable safety profile.
Emerging evidence also supports benefits for bone density, muscle mass, and cognitive function, though these indications are still under investigation.
The safety profile at appropriate female doses is reassuring. Common side effects are mild and dose-dependent, including acne, increased body hair, and oily skin. These are generally manageable with dose adjustment. Serious adverse effects are rare at physiological replacement doses.
Despite the evidence, testosterone remains conspicuously absent from most women’s HRT programs. There are several reasons for this gap.
Regulatory gaps mean there is no FDA-approved testosterone product specifically for women in the United States. This doesn’t mean testosterone for women is inappropriate — it means providers must prescribe compounded formulations or use male-approved products at adjusted doses. This requires more clinical expertise and comfort with off-label prescribing.
Outdated attitudes persist among some providers who associate testosterone exclusively with male health and are hesitant to prescribe it for women. The clinical evidence has moved far ahead of this attitude, but it remains a barrier to access.
Simplistic program design at many telehealth competitors means they offer estrogen and perhaps progesterone, but stop there. Adding testosterone requires additional clinical sophistication, monitoring, and formulation options that simpler programs aren’t set up to provide.
Luvo’s hormone replacement program is designed to provide the complete hormonal picture. For many women, adding testosterone to their estradiol regimen is the intervention that transforms their HRT experience from adequate to truly life-changing.
Visit Luvo’s hormone replacement program to discuss whether testosterone should be part of your protocol.
Of all the symptoms of menopause, vaginal and urogenital changes may be the most underreported and undertreated. Up to 80% of postmenopausal women experience genitourinary syndrome of menopause (GSM) — a term that encompasses vaginal dryness, burning, irritation, painful intercourse (dyspareunia), urinary urgency and frequency, and recurrent urinary tract infections.
Unlike hot flashes, which often improve over time, GSM is progressive. Without treatment, it gets worse with each passing year as the estrogen-dependent tissues of the vagina and urinary tract continue to thin, lose elasticity, and become increasingly fragile.
The good news: localized vaginal estradiol is one of the most effective, safest, and most well-tolerated treatments in all of HRT. Luvo offers two vaginal estradiol formulations — vaginal gel and vaginal tablets — specifically for this purpose.
GSM occurs because the vaginal and urethral tissues are highly estrogen-dependent. When estrogen levels drop during and after menopause, these tissues undergo significant changes.
The vaginal epithelium thins from multiple cell layers to just a few, becoming fragile and easily irritated. Vaginal pH rises from its normal acidic range (3.5–4.5) to neutral or alkaline levels, disrupting the protective microbial environment and increasing susceptibility to infections. Blood flow to the vaginal and urethral tissues decreases, reducing natural lubrication and tissue health. The vaginal walls lose elasticity and may actually narrow and shorten. The urethral lining thins, contributing to urinary symptoms.
These changes can profoundly affect quality of life and intimate relationships. Many women avoid sexual activity entirely because of pain, and urinary symptoms can restrict daily activities. Yet studies consistently show that fewer than 25% of affected women receive treatment — often because they don’t mention symptoms to their provider, or their provider doesn’t ask.
Vaginal estradiol delivers the hormone directly to the tissues that need it most. Unlike systemic estradiol (tablets, cream, or patches), vaginal formulations are designed for localized action with minimal absorption into the bloodstream.
When applied vaginally, estradiol is absorbed by the estrogen-receptor-rich cells of the vaginal epithelium. It stimulates cell proliferation and maturation, restoring the vaginal lining to a healthier, more resilient state. Vaginal pH normalizes, protective lactobacilli return, lubrication improves, and the tissue regains elasticity and blood flow.
The systemic absorption of vaginal estradiol is very low — significantly lower than oral or transdermal estradiol. Blood estradiol levels with vaginal formulations typically remain within the normal postmenopausal range. This is why vaginal estradiol is considered safe for many women who cannot use systemic HRT, including some breast cancer survivors (though this should always be discussed with an oncologist).
Luvo offers two formulations for localized estradiol delivery.
Estradiol vaginal gel is applied intravaginally using a pre-measured applicator. The gel distributes evenly across the vaginal walls, providing broad tissue contact. Many women find the gel comfortable and easy to use. Application is typically daily for the initial treatment period, then reduced to a maintenance schedule of 2–3 times per week. The gel formulation can also provide some benefit to the external vulvar area during application.
Estradiol vaginal tablets are small tablets inserted into the vagina using a disposable applicator. They dissolve and release estradiol locally. The tablet format is clean, mess-free, and appeals to women who prefer a solid formulation over a gel. Like the gel, initial treatment is usually daily, transitioning to a maintenance schedule.
Both formulations are effective for treating vaginal dryness, painful intercourse, vaginal atrophy, and urinary symptoms. The choice between them often comes down to personal preference and comfort.
Explore Luvo’s estradiol vaginal gel and estradiol vaginal tablets.
Understanding whether you need localized therapy, systemic therapy, or both is an important conversation to have with your Luvo provider.
Vaginal estradiol alone is appropriate if your primary symptoms are urogenital — vaginal dryness, painful sex, urinary issues — and you don’t have significant hot flashes, sleep disruption, or other systemic symptoms. It’s also a good option for women who have contraindications to systemic estrogen or prefer to avoid it.
Systemic estradiol (tablets, cream, or patches) is needed if you have systemic symptoms like hot flashes, night sweats, mood changes, or bone density concerns. Systemic therapy also provides some benefit to vaginal tissues, though many women find that adding localized vaginal estradiol provides more complete urogenital relief.
Combination therapy — systemic plus vaginal — is appropriate for women who have both systemic and significant urogenital symptoms. The systemic dose is set for overall symptom management, while vaginal estradiol provides the concentrated local effect the vaginal tissues need.
Luvo’s program supports all three approaches, and your provider will recommend the strategy that best addresses your symptom profile. Visit the hormone replacement program page to get started.
Estradiol is the primary estrogen your ovaries produce during your reproductive years, and it’s the gold standard for hormone replacement therapy. When your provider prescribes estradiol for menopause, you’re receiving the bioidentical hormone — chemically identical to what your body made naturally.
But how that estradiol reaches your bloodstream matters more than most women realize. Luvo offers three systemic estradiol formulations — tablets, cream, and patches — and each has distinct absorption characteristics, clinical advantages, and lifestyle implications. Understanding these differences helps you and your Luvo provider choose the option that’s genuinely right for you.
Oral estradiol tablets are the most traditional form of systemic HRT. You swallow a tablet daily, and the estradiol is absorbed through the GI tract and processed by the liver before entering the general circulation.
This “first-pass” hepatic metabolism is the defining characteristic of oral estradiol. As the hormone passes through the liver, it triggers the production of various proteins including clotting factors and sex hormone-binding globulin (SHBG). This hepatic effect is clinically relevant — it’s the reason oral estrogen carries a slightly higher risk of venous thromboembolism (blood clots) compared to transdermal routes.
That said, oral estradiol remains safe and effective for many women, particularly those at low baseline risk for clotting events. The advantages include simplicity and familiarity (it’s just a pill), well-established dosing protocols with decades of clinical data, and effective relief of hot flashes, night sweats, and other systemic symptoms.
Luvo’s estradiol tablets are bioidentical estradiol — not the conjugated equine estrogens (Premarin) used in older studies. This distinction matters for both efficacy and safety.
Estradiol cream is applied to the skin — typically the inner arm, thigh, or abdomen — where it absorbs through the dermis directly into the bloodstream, bypassing the liver entirely.
This avoidance of first-pass metabolism is the primary clinical advantage of transdermal estradiol. Without hepatic processing, transdermal estradiol does not increase clotting factor production, making it a safer option for women with elevated thrombotic risk, including those with obesity, a history of migraines with aura, or moderate cardiovascular risk factors.
Estradiol cream offers flexibility in dosing because the amount applied can be adjusted more granularly than with fixed-dose tablets or patches. This can be advantageous during the early titration phase when finding the right dose.
The practical considerations include a brief daily application routine (1–2 minutes), a short drying period before dressing, and the need to avoid washing the application site for several hours. Some women prefer the sense of control that topical application provides.
Estradiol patches are adhesive patches applied to the skin, typically on the lower abdomen or hip, and replaced once or twice weekly depending on the formulation. Like cream, patches deliver estradiol transdermally, bypassing liver metabolism.
The standout advantage of patches is steady-state hormone delivery. While oral estradiol produces peaks and troughs as the tablet is absorbed and metabolized, patches release a consistent amount of estradiol around the clock. This steady delivery can result in fewer hormonal fluctuations and more consistent symptom control.
Patches share the safety advantages of all transdermal delivery — no increased clotting risk from hepatic stimulation. They’re also the most “set-and-forget” option, requiring attention only once or twice per week.
The trade-offs include potential skin irritation at the application site (rotating sites helps), adhesion issues in humid climates or with heavy sweating, and visibility (though patches can be placed in areas covered by clothing).
For women who want effective HRT with minimal daily routine and the safest thrombotic profile, patches are often the preferred choice.
Your Luvo provider will guide this decision based on clinical factors and your preferences, but here’s a general framework.
Choose tablets if you prefer the simplicity of a daily pill, have no elevated risk for blood clots, and want a well-established, familiar treatment format.
Choose cream if you have risk factors for thrombosis, prefer flexible dosing, want transdermal safety benefits, and don’t mind a brief daily application routine.
Choose patches if you want the most consistent hormone levels, prefer a twice-weekly routine over daily, want transdermal safety with maximum convenience, and don’t have skin sensitivity to adhesives.
Many women try one formulation and switch to another based on their experience — and Luvo’s program makes switching straightforward. The goal is finding the delivery method that integrates most naturally into your life while providing optimal symptom relief.
Visit Luvo’s hormone replacement program to discuss your options with a provider, or explore each formulation: estradiol tablets, estradiol cream, and estradiol patches.
If your understanding of hormone replacement therapy is shaped by headlines from 20 years ago, it’s time for an update. The 2002 Women’s Health Initiative (WHI) study sent shockwaves through medicine, leading millions of women to abandon HRT and a generation of physicians to stop prescribing it. But the decades since have brought dramatic clarity: the WHI’s findings were widely misinterpreted, and the resulting fear of HRT caused immeasurable harm to women who could have benefited from treatment.
Today, major medical organizations including the North American Menopause Society, the Endocrine Society, and the American College of Obstetricians and Gynecologists affirm that HRT is safe and effective for most women experiencing menopause symptoms, particularly when started within 10 years of menopause onset.
Luvo’s hormone replacement program is built on this modern evidence base. With 10 medication options spanning estradiol formulations, testosterone therapy, and non-hormonal alternatives, it offers a level of treatment personalization that most competitors simply can’t match.
Menopause isn’t a single event — it’s a transition that typically spans several years. The process begins in perimenopause, usually in the mid-40s, when the ovaries begin producing less estrogen and progesterone. Hormone levels fluctuate unpredictably, causing symptoms that can range from mildly annoying to severely disruptive.
Menopause is officially reached when 12 consecutive months pass without a menstrual period, typically around age 51. At this point, the ovaries have largely ceased producing estrogen, and levels of this hormone remain permanently low.
Estrogen isn’t just a reproductive hormone. It has receptors throughout the body — in the brain, bones, cardiovascular system, urogenital tract, skin, and joints. When estrogen declines, the effects cascade across multiple systems: vasomotor symptoms like hot flashes and night sweats, sleep disruption, mood changes and cognitive fog, vaginal dryness and urogenital atrophy, bone density loss, cardiovascular risk changes, joint pain and muscle loss, and skin and hair changes.
Testosterone also declines in women, though more gradually. By menopause, a woman’s testosterone level may be half what it was in her 20s, contributing to decreased libido, reduced energy, and loss of muscle mass.
HRT addresses these declines by restoring hormones to levels that alleviate symptoms and protect long-term health.
What sets Luvo apart from competitors is the breadth of our medication options. Managing hormonal decline isn’t one-size-fits-all, and neither is our program.
Estradiol is available in five formulations: oral tablets for systemic hormone delivery, transdermal cream for absorption through the skin, transdermal patches for steady-state hormone levels, vaginal gel for localized urogenital symptom relief, and vaginal tablets for targeted vaginal atrophy treatment.
Testosterone for women is available in three formulations: injection, oral tablets, and topical gel — addressing the often-overlooked role of testosterone in female vitality, libido, and body composition.
Non-hormonal options include Paroxetine, the only FDA-approved non-hormonal treatment for vasomotor symptoms, and Desvenlafaxine, an SNRI with strong evidence for hot flash reduction. These serve women who cannot or prefer not to use hormonal therapy.
This 10-medication toolkit means your Luvo provider can design a protocol precisely matched to your symptoms, health history, preferences, and risk profile.
HRT is most clearly indicated for women experiencing moderate to severe vasomotor symptoms such as hot flashes and night sweats, women under 60 or within 10 years of menopause onset (the “window of opportunity” for cardiovascular and bone benefits), women with premature ovarian insufficiency or early menopause (before age 40), women with significant urogenital symptoms like vaginal dryness, painful intercourse, or recurrent UTIs, and women at elevated risk for osteoporosis.
HRT may require additional evaluation or alternatives for women with a history of breast cancer, women with active cardiovascular disease or a history of blood clots, women with undiagnosed vaginal bleeding, and women with active liver disease.
Luvo’s providers conduct thorough health evaluations to determine the safest and most effective approach for each patient. For women who cannot use estrogen, our non-hormonal options provide meaningful symptom relief.
Explore Luvo’s full hormone replacement program to learn more.
Losing weight is hard. Keeping it off is harder. This isn't a motivational platitude — it's a well-documented physiological reality. After weight loss, the body undergoes hormonal and metabolic changes that actively promote weight regain: hunger hormones increase, metabolic rate decreases, and the brain's reward response to food intensifies.
This is where GLP-1 microdosing offers a particularly compelling advantage. Unlike crash diets or short-term medication courses, Luvo's microdosing program is designed with the long game in mind — not just helping you lose weight, but helping you keep it off in a way that's medically sound and practically sustainable.
One of the most important conversations in obesity medicine right now concerns what happens when patients discontinue GLP-1 medications. The data is sobering: studies have shown that patients regain approximately two-thirds of their lost weight within a year of stopping semaglutide.
This happens because GLP-1 medications are treating the underlying biology of obesity — not curing it. When the medication is removed, the biological drivers of weight gain reassert themselves. It's analogous to stopping blood pressure medication: the underlying condition hasn't been resolved, so the problem returns.
This reality argues strongly for a long-term treatment approach. And if medication is going to be used long-term, the dose, side-effect profile, and cost all need to be sustainable — which is exactly what microdosing optimizes for.
Standard-dose GLP-1 therapy was developed with a focus on maximum weight loss in clinical trial timeframes. But clinical trials and real life are different. In real life, the question isn't just "how much weight can I lose in 72 weeks?" but "what approach can I sustain for years or even decades?"
Microdosing excels here for several reasons.
Tolerability sustains adherence. The number one predictor of long-term success with any medication is whether you keep taking it. Lower doses mean fewer side effects, which means you're far more likely to stay on treatment. Cost sustainability matters too. Long-term medication use requires financial planning. Microdosing can reduce medication costs, making indefinite use more feasible. Additionally, lower long-term risk is important because while GLP-1 medications have strong safety profiles, using the lowest effective dose over the long term is a sound medical principle — it minimizes exposure while maintaining benefit. Finally, quality of life at lower doses is better. You can enjoy food, socialize around meals, and live normally — things that can be challenging at higher doses where appetite suppression can feel overwhelming.
While Luvo's microdosing program may support long-term medication use, the ideal scenario is that medication buys you time to build lasting habits. The appetite reduction and behavioral changes you experience on GLP-1 medication create a window of opportunity to develop a healthier relationship with food and exercise.
Strategies that complement microdosing for long-term success include progressive strength training, which builds lean mass, increases resting metabolic rate, and creates a physiological buffer against weight regain. Protein-focused nutrition is also key — adequate protein intake (0.7-1g per pound of body weight) supports muscle preservation and enhances satiety independent of medication. Consistent sleep habits matter because poor sleep increases ghrelin (hunger hormone) and decreases leptin (satiety hormone), working against your medication. Finally, stress management is important because chronic stress drives cortisol-mediated fat storage and emotional eating — skills like mindfulness and stress management create lasting resilience.
Luvo's program integrates these principles into your treatment plan, recognizing that medication is most effective as part of a comprehensive approach.
As you reach your weight-loss goal and transition into maintenance, your microdose may be adjusted. Some patients find they can reduce their dose further during maintenance while maintaining their results. Others find that their initial microdose remains the right level.
This is one of the advantages of Luvo's personalized approach — your provider monitors your progress and adjusts treatment as your needs evolve. Maintenance isn't an afterthought; it's a planned phase of your program.
Some patients eventually taper off medication entirely while maintaining their results through lifestyle habits built during treatment. Others benefit from ongoing low-dose maintenance. Both approaches are valid, and Luvo's clinical team helps you navigate this decision based on your individual biology and goals.
Luvo's microdosing program isn't just about the number on the scale. It's about creating a sustainable path to better health that you can maintain for life.
Whether you use microdosing as a bridge to build healthier habits, a long-term maintenance tool, or some combination of both, Luvo's clinical team is with you at every stage. Our program offers the medication flexibility (semaglutide or tirzepatide, injection or tablet), clinical expertise, and ongoing support that a genuine long-term health partnership requires.
Competitors may promise fast results, but sustainable results are what matter. Explore Luvo's microdosing program to start building your long-term weight management plan today.
The appeal of microdosing GLP-1 medications is broad — fewer side effects, more sustainable weight loss, and a personalized approach that respects your body's response to treatment. But like any medical intervention, it's not appropriate for everyone.
This article will help you understand whether Luvo's microdosing program with semaglutide or tirzepatide might be a good fit for you, what the eligibility criteria are, and what you should realistically expect from treatment.
GLP-1 medications for weight management are generally prescribed for adults with a BMI of 30 or higher (obesity) or a BMI of 27 or higher with at least one weight-related comorbidity such as Type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease.
These criteria apply whether you're pursuing standard dosing or microdosing. The difference isn't who qualifies — it's how the treatment is delivered.
At Luvo, your eligibility is assessed by a licensed provider during your initial consultation. This includes a review of your medical history, current medications, and health goals.
While anyone eligible for GLP-1 therapy can benefit from microdosing, certain patient profiles may find this approach particularly valuable.
Side-effect-sensitive patients — if you've tried GLP-1 medications before and couldn't tolerate the side effects, or if you're generally sensitive to medications, microdosing's lower-dose approach may make treatment feasible. Patients prioritizing sustainability — if your goal is long-term weight management rather than rapid weight loss, microdosing's gradual approach aligns well with sustainable habits. Those on a budget — lower doses can mean lower medication costs, making long-term treatment more financially manageable. Patients with moderate weight-loss goals — if you need to lose 15-30 pounds rather than 100+, microdosing may provide sufficient effect without the intensity of maximum dosing. People who want to maintain muscle mass — the slower weight loss associated with microdosing, combined with proper nutrition and exercise, may help preserve lean body mass.
There are important contraindications for GLP-1 medications that apply regardless of dose. You should not use semaglutide or tirzepatide if you have a personal or family history of medullary thyroid carcinoma, a history of Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), a known hypersensitivity to semaglutide or tirzepatide, a history of pancreatitis (relative contraindication — discuss with your provider), or if you are pregnant, planning to become pregnant, or breastfeeding.
Additionally, these medications require careful consideration in patients with gastroparesis or severe GI motility disorders, a history of eating disorders, severe renal impairment, or a history of gallbladder disease.
Luvo's providers conduct thorough screening to ensure safety before prescribing any medication.
Understanding what microdosing can and cannot do is crucial for a positive treatment experience.
Microdosing CAN provide meaningful, clinically significant weight loss (typically 8-15% of body weight); substantially reduce appetite and food cravings; improve metabolic markers; and offer a more tolerable treatment experience with fewer side effects.
Microdosing may NOT produce the dramatic 20%+ weight loss seen with maximum-dose tirzepatide; work as quickly as higher-dose protocols; eliminate the need for dietary and lifestyle changes; or be a standalone solution without addressing underlying habits.
The best results come from combining microdosing with proper nutrition, regular physical activity, adequate sleep, and stress management. Luvo's program supports this holistic approach.
If you think you might be a good candidate for GLP-1 microdosing, the first step is a clinical consultation. Luvo makes this process simple and accessible — you can complete your health assessment online and connect with a licensed provider who specializes in the microdosing approach.
During your consultation, your provider will confirm your eligibility, discuss your goals and preferences, recommend a specific medication (semaglutide or tirzepatide) and formulation (injection or tablet), and create a personalized treatment plan.
Visit Luvo's microdosing program page to begin your assessment, or explore our medication options: microdosing semaglutide injection, microdosing semaglutide tablets, microdosing tirzepatide injection, and microdosing tirzepatide tablets.
